164 related articles for article (PubMed ID: 12526918)
1. Expression of sorcin predicts poor outcome in acute myeloid leukemia.
Tan Y; Li G; Zhao C; Wang J; Zhao H; Xue Y; Han M; Yang C
Leuk Res; 2003 Feb; 27(2):125-31. PubMed ID: 12526918
[TBL] [Abstract][Full Text] [Related]
2. Expression and clinical implication of soluble resistance-associated calcium-binding protein gene and multi-drug resistance gene in leukemia.
Li G; Tan Y; Yang C; Zhao C; Zhao H; Wang J; Xue Y; Han M; Qian L; Zhao C
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):370-4. PubMed ID: 12408767
[TBL] [Abstract][Full Text] [Related]
3. A new PCR MIMIC strategy to quantify low mdr1 mRNA levels in drug resistant cell lines and AML blast samples.
Illmer T; Schaich M; Oelschlägel U; Nowak R; Renner U; Ziegs B; Subat S; Neubauer A; Ehninger G
Leuk Res; 1999 Jul; 23(7):653-63. PubMed ID: 10400187
[TBL] [Abstract][Full Text] [Related]
4. Expression and clinical implications of the soluble drug resistance-related calcium-binding protein (sorcin) gene in leukemia patients.
Li G; Tan Y; Yang C; Zhao C; Zhao H; Wang J; Xue Y; Han M; Qian L; Zhao C
Zhonghua Xue Ye Xue Za Zhi; 2002 Jun; 23(6):293-6. PubMed ID: 12411058
[TBL] [Abstract][Full Text] [Related]
5. Sorcin, an important gene associated with multidrug-resistance in human leukemia cells.
Zhou Y; Xu Y; Tan Y; Qi J; Xiao Y; Yang C; Zhu Z; Xiong D
Leuk Res; 2006 Apr; 30(4):469-76. PubMed ID: 16213583
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of sorcin is associated with multidrug resistance in leukemia cells via up-regulation of MDR1 expression through cAMP response element-binding protein.
Yamagishi N; Nakao R; Kondo R; Nishitsuji M; Saito Y; Kuga T; Hatayama T; Nakayama Y
Biochem Biophys Res Commun; 2014 Jun; 448(4):430-6. PubMed ID: 24796664
[TBL] [Abstract][Full Text] [Related]
7. [Treatment outcome of multidrug resistance related mRNA expression and c-jun-N-terminal kinase activity in patients with acute myeloid leukemia].
Do JH; Oh SH; Song EJ; Chung JS; Kang CD; Lee EY
Korean J Lab Med; 2007 Aug; 27(4):229-36. PubMed ID: 18094581
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of SORCIN is a Prognostic Biomarker for Multidrug-Resistant Pediatric Acute Lymphoblastic Leukemia and Correlates with Upregulated MDR1/P-gp.
Dabaghi M; Rahgozar S; Moshtaghian J; Moafi A; Abedi M; Pourabutaleb E
Genet Test Mol Biomarkers; 2016 Sep; 20(9):516-21. PubMed ID: 27382961
[TBL] [Abstract][Full Text] [Related]
9. Impact of the expression of P glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat shock protein 27 on response to induction therapy and long-term survival in patients with de novo acute myeloid leukemia.
Kasimir-Bauer S; Beelen D; Flasshove M; Noppeney R; Seeber S; Scheulen ME
Exp Hematol; 2002 Nov; 30(11):1302-8. PubMed ID: 12423683
[TBL] [Abstract][Full Text] [Related]
10. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases.
Leith CP; Chen IM; Kopecky KJ; Appelbaum FR; Head DR; Godwin JE; Weick JK; Willman CL
Blood; 1995 Sep; 86(6):2329-42. PubMed ID: 7545025
[TBL] [Abstract][Full Text] [Related]
11. Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells.
Kawakami M; Nakamura T; Okamura N; Komoto C; Markova S; Kobayashi H; Hashimoto N; Okumura K; Sakaeda T
Biol Pharm Bull; 2007 Jun; 30(6):1065-73. PubMed ID: 17541155
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
13. [Influence of tetrandrine on SORCIN gene expression in K562/A02 cell line].
Li J; Chen BA; Zhu MS; Gao F; Ding JH; Gao C; Sun YY; Cheng J; Wang J; Zhao G; Song HH; Ma Y; Bao W; Sun XC; Cheng HY; Xu WL; Shen HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):65-9. PubMed ID: 18315902
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins.
Hu Y; Cheng X; Li S; Zhou Y; Wang J; Cheng T; Yang M; Xiong D
Cancer Chemother Pharmacol; 2013 Oct; 72(4):789-98. PubMed ID: 24013575
[TBL] [Abstract][Full Text] [Related]
15. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia.
Zhou DC; Zittoun R; Marie JP
Leukemia; 1995 Oct; 9(10):1661-6. PubMed ID: 7564506
[TBL] [Abstract][Full Text] [Related]
16. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
17. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
18. A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
Advani AS; Shadman M; Ali-Osman F; Barker A; Rybicki L; Kalaycio M; Sekeres MA; de Castro CM; Diehl LF; Moore JO; Beaven A; Copelan E; Sobecks R; Talea P; Rizzieri DA
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):473-6. PubMed ID: 21156465
[TBL] [Abstract][Full Text] [Related]
19. Absolute levels of MDR-1, MRP, and BCL-2 MRNA and tumor remission in acute leukemia.
Köhler T; Leiblein S; Borchert S; Eller J; Rost AK; Lassner D; Krahl R; Helbig W; Wagner O; Remke H
Adv Exp Med Biol; 1999; 457():177-85. PubMed ID: 10500792
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P
Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
